医学
经前期烦躁障碍
精神科
协商一致会议
排卵
达那唑
心理学
妇科
内科学
子宫内膜异位症
激素
月经周期
作者
Tracy Nevatte,Patrick O’Brien,Torbjörn Bäckström,Candace Brown,Lorraine Dennerstein,Jean Endicott,C. Neill Epperson,Elias Eriksson,Ellen W. Freeman,Uriel Halbreich,Kamariah Ismail,Nicholas Panay,Teri Pearlstein,Andrea J. Rapkin,Robert L. Reid,David R. Rubinow,Peter J. Schmidt,Meir Steiner,John Studd,Inger Sundström‐Poromaa,Kimberly A. Yonkers
标识
DOI:10.1007/s00737-013-0346-y
摘要
The second consensus meeting of the International Society for Premenstrual Disorders (ISPMD) took place in London during March 2011. The primary goal was to evaluate the published evidence and consider the expert opinions of the ISPMD members to reach a consensus on advice for the management of premenstrual disorders. Gynaecologists, psychiatrists, psychologists and pharmacologists each formally presented the evidence within their area of expertise; this was followed by an in-depth discussion leading to consensus recommendations. This article provides a comprehensive review of the outcomes from the meeting. The group discussed and agreed that careful diagnosis based on the recommendations and classification derived from the first ISPMD consensus conference is essential and should underlie the appropriate management strategy. Options for the management of premenstrual disorders fall under two broad categories, (a) those influencing central nervous activity, particularly the modulation of the neurotransmitter serotonin and (b) those that suppress ovulation. Psychotropic medication, such as selective serotonin reuptake inhibitors, probably acts by dampening the influence of sex steroids on the brain. Oral contraceptives, gonadotropin-releasing hormone agonists, danazol and estradiol all most likely function by ovulation suppression. The role of oophorectomy was also considered in this respect. Alternative therapies are also addressed, with, e.g. cognitive behavioural therapy, calcium supplements and Vitex agnus castus warranting further exploration.
科研通智能强力驱动
Strongly Powered by AbleSci AI